Next week, our CFO & EVP, Corporate Development, Neha Krishnamohan will be at the ???????? ?????? ???????? ?????????????? ???? ?????? ???????? next week presenting on the potential of NK cells as an allogeneic cell therapy approach in autoimmune disease. See the agenda here: https://lnkd.in/eiUpMy4 #CGMesa24 #AlloNK #NKcell #NKcells #NKcelltherapy #clinicaltrials #autoimmunedisease #autoimmunity #immunology #autoimmune #lupus #lupusnephritis
Artiva Biotherapeutics
生物技术研究
San Diego，California 9,777 位关注者
We are dedicated to making safe and effective cell therapies accessible to any cancer patient who may benefit.
关于我们
Artiva Biotherapeutics is an immunotherapy company with the ability to produce off-the-shelf, allogeneic NK cell therapies at a massive scale. Our mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Our lead program, AlloNK?, is an allogeneic, non-genetically modified NK cell therapy candidate designed to enhance the activity of monoclonal antibodies or NK cell engagers. AlloNK is currently in clinical trials in combination with rituximab for treatment of systemic lupus erythematosus (SLE) in patients with active lupus nephritis and for treatment of Non-Hodgkin Lymphoma, as well as in combination with Affimed’s innate cell engager AFM13 for the treatment of patients with relapsed/refractory CD30-positive lymphomas.
- 网站
-
https://www.artivabio.com
Artiva Biotherapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- San Diego，California
- 类型
- 私人持股
- 创立
- 2019
- 领域
- cell therapy、cancer、nk cells、nk cell therapy和car-nk
地点
-
主要
获取路线
5505 Morehouse Drive, Suite 100
US，California，San Diego，92121
Artiva Biotherapeutics员工
动态
-
We were honored to present at the ???????????? ???????? ???????????? ???????????????????? ???????????????????? in New York last week and discuss how allogeneic NK cell therapies can transform the treatment of autoimmune diseases. ?? If you missed it, watch the webcast here: https://lnkd.in/gnjFAMS2 #CantorHCC #AlloNK #NKcell #NKcells #NKcelltherapy #clinicaltrials #autoimmunedisease #autoimmunity #immunology #autoimmune #lupus #lupusnephritis #biotech #InvestorEvent
-
-
Our CEO Fred Aslan will be presenting at the ???????????? ???????? ???????????? ???????????????????? ????????????????????. Join for a Fireside Chat on ?????????????????? ???????? ???? ??:???? ???? ?????? to learn more about the opportunity for allogeneic NK cell therapies to transform the treatment of autoimmune diseases. ??? Read the press release for more details: https://lnkd.in/gvbAWyDx ?? Watch the webcast here: https://lnkd.in/gDkVQxAJ #CantorHCC #AlloNK #NKcell #NKcells #NKcelltherapy #clinicaltrials #autoimmunedisease #autoimmunity #immunology #autoimmune #lupus #lupusnephritis #biotech #InvestorEvent
-
-
Artiva Biotherapeutics announces strong Q2 2024 financial results and recent business milestones. We’re excited to share our progress in Q2 2024, marked by important achievements: ?? Successfully completed an upsized $179.0 million IPO, strengthening our balance sheet ?? Initiated treatment for the first patient in an investigator-initiated basket trial of AlloNK? exploring multiple autoimmune indications ?? Treated the first patient in our Phase 1/1b trial targeting class III/IV lupus nephritis (LN) and expanded the trial to include patients with systemic lupus erythematosus (SLE) without kidney involvement At Artiva, we remain committed to advancing innovative NK cell therapies for patients with serious unmet medical needs. Read the full release here: https://lnkd.in/gxskVSPd #biotech #biopharma #healthcareinnovation #ArtivaBiotherapeutics #AlloNK #lupus #NKcell #NKcells #NKcelltherapy #autoimmunedisease #cancer
-
Our CEO Fred Aslan spoke with Brian Orelli, PhD, of BiotechTV about our recent #IPO, the potential of NK cell therapy to achieve deep B cell depletion to treat autoimmune disease, and how Artiva’s platform can make these cell therapies broadly accessible to patients who need them. Watch below or check out the interview here: https://lnkd.in/gFpZ5DNX #biotech #AlloNK #lupus #NKcell #NKcells #NKcelltherapy #autoimmunedisease #cancer
?????????????? ????????: Checking in with Artiva Biotherapeutics' CEO Fred Aslan after the NK cell focused company's $167 million IPO. He describes what the funds will enable Artiva to do in the clinic, and why he believes the company's non-modified NK cell approach is the best platform for using a cell therapy for autoimmune conditions. Full video: https://lnkd.in/gFpZ5DNX BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
Thank you to Nasdaq for celebrating our very first trade as $ARTV on July 19th. And big thanks to our team, partners, investors, and supporters for helping us achieve this important milestone! We are energized and deeply committed to making cell therapies broadly accessible to patients with autoimmune disease and cancer.? #biotech #IPO #AlloNK #lupus #NKcell #NKcelltherapy #autoimmunedisease #cancer #NasdaqListed
-
We are pleased to announce the pricing of an upsized $167.0 million initial public offering on the Nasdaq exchange.?Read the release here: https://lnkd.in/gcTfTMJt #biotech #IPO #AlloNK #lupus #NKcell #NKcelltherapy #autoimmunedisease
-
-
“Move over CAR-T: the potential of NK cells in cell therapy” On this pharmaphorum podcast, Artiva’s CEO, Dr. Fred Aslan, talks with host Jonah Comstock about the potential of NK cells as an allogeneic cell therapy approach in autoimmune disease and the importance of a robust manufacturing process. Listen to the podcast on pharmaphorum’s website, which has a podcast player or the option to download the episode. It also has links to find the podcast on iTunes, Spotify, and Stitcher. https://lnkd.in/gc6vDjRf #AlloNK #NKcell #NKcells #clinicaltrials #clinicaltrial #autoimmunedisease #lupus #autoimmunity #celltherapy
-
We were thrilled to be with #LupusTherapeutics and @LupusResearchAlliance at the fourth annual Lupus Clinical Investigators Network (LuCIN) Community Meeting, bringing together clinical investigators, study coordinators, people with lupus and industry partners to participate in discussions around critical research initiatives and the latest approaches in lupus treatment. Visit https://bit.ly/LuCIN2024 to learn more about LuCIN. #LupusClinicalResearch #LuCINCommunity #LupusAwarenessMonth
-
-
Join us in raising awareness for Lupus Day! #WorldLupusDay #MakeLupusVisible #may10worldlupusday ????
-